Immunology · Transplant RejectionTrial Updateclinicalmid-term

Fostamatinib Trial for Lung Transplant Patients with Donor-Specific Antibodies

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/28/2026, 12:32:02 PM

Assessment confidence: 70% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of fostamatinib in lung transplant patients with donor-specific antibodies could significantly enhance its therapeutic profile and market potential. Success in this trial may lead to a new treatment option for a high-risk patient population, influencing competitive dynamics in transplant immunology. Regulatory context from FDA (FDA AP — FOSTAMATINIB DISODIUM (ORIG)) supports the near-term read. Assessment grounded in 14 ranked evidence items (7 high-relevance).

Strategic Assessment

Success in this trial may enhance the therapeutic profile of fostamatinib and expand its market potential in transplant-related complications. The strongest clinical anchor is Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (ClinicalTrials.gov), entity match (fostamatinib). In Immunology · Transplant Rejection, 4 regulatory and 0 competitive items passed relevance filtering for fostamatinib.

Competitive Pressure

The most relevant competitive pressure comes from This trial could position fostamatinib as a potential treatment option for a high-risk patient population, impacting competitive dynamics in transplant immunology..

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — FOSTAMATINIB DISODIUM (ORIG) (FDA). Entity match (fostamatinib); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. Positive trial results could facilitate regulatory approval for fostamatinib in a new indication, impacting labeling and compliance requirements.

Key Risks

Elevated medium regulatory exposure for fostamatinib could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, fostamatinib could capture a share of the transplant-related complications market, potentially increasing revenue and market positioning against competitors.
How we engage and involve patients and the public in our regulatory decision-making.
Success in this trial may enhance the therapeutic profile of fostamatinib and expand its market potential in transplant-related complications.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and safety data, particularly the impact on rejection rates and patient outcomes.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — FOSTAMATINIB DISODIUM (ORIG)
FDAhigh relevance
Entity match (fostamatinib); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAhigh relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAhigh relevance
Moderate corpus alignment
FDA document
View source

Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
ClinicalTrials.govhigh relevance
Entity match (fostamatinib)
FDA document
View source
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source

No evidence in this category.

Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Thoracic paravertebral block with different doses of liposomal bupivacaine versus ropivacaine for postoperative analgesia in single-port thoracoscopic lung surgery: a randomized clinical trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Unveiling the cognitive fog in lung cancer patients: non-invasive exploration of blood-brain barrier disruption and brain structural changes.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

fostamatinib

Commercial impact

medium

If successful, fostamatinib could capture a share of the transplant-related complications market, potentially increasing revenue and market positioning against competitors.

Regulatory impact